A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.
